Synonym
FM-381; FM 381; FM381.
IUPAC/Chemical Name
(E)-2-cyano-3-(5-(1-cyclohexyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-2-yl)furan-2-yl)-N,N-dimethylacrylamide
InChi Key
GJMZWYLOARVASY-NTCAYCPXSA-N
InChi Code
InChI=1S/C24H24N6O2/c1-29(2)24(31)15(13-25)12-17-8-9-20(32-17)23-28-19-14-27-22-18(10-11-26-22)21(19)30(23)16-6-4-3-5-7-16/h8-12,14,16H,3-7H2,1-2H3,(H,26,27)/b15-12+
SMILES Code
O=C(N(C)C)/C(C#N)=C/C(O1)=CC=C1C2=NC3=CN=C(NC=C4)C4=C3N2C5CCCCC5
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
AK kinases are effectors of the JAK-STAT signaling pathway, which is triggered by ligand binding to a cognate receptor resulting in activation of JAK by phosphorylation of key tyrosine residues within the catalytic domain. After activation, tyrosine resides in the receptor intracellular region are also phosphorylated which triggers recruitment and phosphorylation of the principal downstream effectors, the STATs. Phosphorylated STATs dimerize and translocate to the nucleus where they initiate transcription of specific responsive genes
Preparing Stock Solutions
The following data is based on the
product
molecular weight
428.50
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Laux J, Forster M, Riexinger L, Schwamborn A, Guezguez J, Pokoj C, Kudolo M,
Berger LM, Knapp S, Schollmeyer D, Guse J, Burnet M, Laufer SA. Pharmacokinetic
Optimization of Small Molecule Janus Kinase 3 Inhibitors to Target Immune Cells.
ACS Pharmacol Transl Sci. 2022 Jul 14;5(8):573-602. doi:
10.1021/acsptsci.2c00054. PMID: 35983274; PMCID: PMC9380220.
2: Forster M, Chaikuad A, Dimitrov T, Döring E, Holstein J, Berger BT, Gehringer
M, Ghoreschi K, Müller S, Knapp S, Laufer SA. Development, Optimization, and
Structure-Activity Relationships of Covalent-Reversible JAK3 Inhibitors Based on
a Tricyclic Imidazo[5,4- d]pyrrolo[2,3- b]pyridine Scaffold. J Med Chem. 2018
Jun 28;61(12):5350-5366. doi: 10.1021/acs.jmedchem.8b00571. Epub 2018 Jun 13.
PMID: 29852068.
